Invest in the Future of Diagnostic Solutions
We are building a tool ready to make diagnostic evaluation for autism faster, more accurate and cheaper.
BlinkLab Dx 1 is a smartphone-based platform seeking FDA 510(k) clearance. Our goal is to aid clinicians and empower parents in detecting developmental concerns early, ultimately improving outcomes for children.
Call for action
Autism prevalence has surged over 2% among children, according to the CDC and WHO.
The challenge
Governments and healthcare providers are urgently seeking new technologies to accelerate diagnostics, enhance accuracy, and reduce medical costs.
Our solution
BlinkLab is at the forefront, delivering a neuroscience-powered, tech-driven, and accessible solution designed to facilitate early diagnosis in young children.
Watch the interview with Brian Leedman, chair of our board.
Our stock
BlinkLab ASX:BB1
-
-
-
Analyst Coverage
East Coach Research: Revolutionising Autism and ADHD Diagnosis with AI-Powered Smartphone Technology
January 2025
Lodge Partners Initiation Research Report BlinkLab Ltd (ASX:BB1) ASD & ADHD
October 2024
Bioshares, Australia’s Independent Biotech Investment Resource, est.1999 – 11
March 2024
Our pipeline
Our R&D pipeline is focused on securing FDA 510(k) clearance and EU regulatory approval for BlinkLab Dx 1 as a diagnostic adjunct for autism and ADHD, positioning it as a transformative tool for early detection.
Studies
Studies
Approval
Authorization
Meet our team!
Our team combines clinical expertise, scientific rigor, and smart solutions to drive innovation.
.png)
"For me it's gratifying to apply neuroscience for improving autism diagnosis and care."
Dr. Henk-Jan Boele, co-founder of BlinkLab, leads a team of neuroscientists, medical doctors, and software developers to bring this mission to life. Founded as a Princeton University startup in 2021, BlinkLab went public on the ASX (ASX:BB1) in April 2024 and is now seeking FDA clearance for its first diagnostic product.
Latest ASX
Announcements
Read more about what
we've been doing!
Awesome! You're now signed up.
You will receive our newsletter. You can opt out via the newsletter.
